Pathological post-transcriptional control of the proteome composition is a central feature of malignancy. Two steps in this pathway, eIF4F-driven cap-dependent mRNA translation and the ubiquitin-proteasome system (UPS), are deregulated in most if not all cancers. We tested a hypothesis that eIF4F is aberrantly activated in human esophageal adenocarcinoma (EAC) and requires elevated rates of protein turnover and proteolysis and thereby activated UPS for its pro-neoplastic function. Here, we show that 80% of tumors and cell lines featuring amplified ERBB2 display an aberrantly activated eIF4F. Direct genetic targeting of the eIF4F in ERBB2-amplified EAC cells with a constitutively active form of the eIF4F repressor 4E-BP1 decreased colony formation and proliferation and triggered apoptosis. In contrast, suppression of m-TOR-kinase activity towards 4E-BP1with rapamycin only modestly inhibited eIF4F-driven cap-dependent translation and EAC malignant phenotype; and promoted feedback activation of other cancer pathways. Our data show that co-treatment with 2 FDA-approved agents, the m-TOR inhibitor rapamycin and the proteasome inhibitor bortezomib, leads to strong synergistic growth-inhibitory effects. Moreover, direct targeting of eIF4F with constitutively active 4E-BP1 is significantly more potent in collaboration with bortezomib than rapamycin. These data support the hypothesis that a finely tuned balance between eIF4F-driven protein synthesis and proteasome-mediated protein degradation is required for the maintenance of ERBB2-mediated EAC malignant phenotype. Altogether, our study supports the development of pharmaceuticals to directly target eIF4F as most efficient strategy; and provides a clear rationale for the clinical evaluation of combination therapy with m-TOR inhibitors and bortezomib for EAC treatment.
INTRODUCTION
ERBB2 (c-erb-B2, HER-2/neu), a transmembrane tyrosine kinase receptor and a member of the epidermal growth factor receptor family, is one of the commonly amplified genes in many human malignancies including upper gastrointestinal (GI) adenocarcinomas 1 where it is over expressed in up to 40% of tumors. 2, 3 ERBB2 plays a key role in growth factor signal transduction and is also involved in the regulation of cell growth, survival, and differentiation. 4, 5 In its normal state, ERBB2 has no known ligand 6 and must pair with other epidermal growth factor receptors (EGFR) for activation. It is then autophosphorylated which initiates a phosphorylation cascade activating multiple intracellular pathways implicated in control of cell proliferation and viability, including RAS/MAP kinase (MAPK) and PI3K, phosphoinositol 3 kinase. 4 Overexpression of ERBB2 through gene amplification leads to homodimerization of the ERBB2 receptor resulting in a constitutively active state triggering aberrant signaling of major RAS/MAPK and PI3K/AKT pathways which activate the mammalian target of rapamycin (mTOR) where these oncogenic pathways converge. Increased mTOR kinase activity in turn leads to phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4E-BP1), a regulator of cap-dependent translation.
Cap-dependent mRNA translation is a key step in epigenetic regulation of proteome composition and activity in a variety of cancers. Accordingly, aberrant activation of the eukaryotic translation initiation complex eIF4F, has been shown in many, if not all, human malignancies; 7--9 and sustained activation of the eIF4F is essential for genesis and maintenance of the neoplastic phenotype. 10--14 In eukaryotic cells, cap-dependent mRNA translation is mediated by a trimeric complex termed eIF4F, which consists of large scaffolding proteins, the eIF4Gs (eIF4GI or eIF4GII); the RNA helicase, eIF4A; and the cap-binding protein eIF4E. 7, 15 Functional activity of the eIF4F complex is negatively regulated by 3 eIF4E binding proteins (4E-BPs), designated 4E-BP1, --BP2, and --BP3. 16, 17 The most abundant and functionally important member of this group is 4E-BP1. The 4E-BPs compete with the eIF4Gs for binding to eIF4E and inhibit formation of eIF4F by sequestering eIF4E in a translationally inactive complex. 18 When phosphorylated by mTOR kinase, 4E-BPs dissociate from eIF4E thereby liberating eIF4E for eIF4F assembly and thus activating cap-dependent translation to regulate cell proliferation. 18, 19 While eIF4G is thought to be a determinant of the capdependent complex formation and stability, several studies have documented an increased expression of eIF4E, a rate-limiting component of eIF4F, in a number of solid tumors, including breast, bladder, colon, esophageal and head and neck cancers. 20--24 Recent clinical data also showed that high expression of phosphorylated 4E-BP1 (p4E-BP1) is associated with poor prognosis, tumor progression, or nodal metastasis in different human cancers, including esophageal squamous cell carcinoma (ESCC). 25 In a variety of cancers, neoplastic growth is associated with both the global increase in protein synthesis and the selective translational stimulation of cancer-related transcripts mediated by eIF4F and the ubiquitin-proteasome system (UPS) stress. Accordingly, the UPS was proposed as a target for anti-cancer interventions, including ERBB2-positive breast cancers. 26--35 Bortezomib (PS341) is the FDA-approved UPS inhibitor of the chymotryptic-like 20S core activity of the 26S proteasome, a large multisubunit protein complex that degrades polyubiquitinated target proteins. Treatment of various cancer cell lines with bortezomib, leads to a reduction in 20S proteasome core activity, global accumulation of polyubiqutinated proteins and as a result an onset of apoptosis. Treatment of ERBB-2 positive breast cancer cell lines with bortezomib leads to a reduction in 20S proteasome core activity. This is associated with intracellular relocalization of ERBB2 (plasma membrane to perinuclear lysosomes), buildup of ubiquitinated and Hsp70-associated receptor, degradation and loss of ERBB2 function and induction of cellular apoptosis. 30 Bortezomib produces a dramatic (20-to 40-fold) sequential increase in polyubiquitinated ERBB2. 31 Combined treatment of ERBB2-positive breast cancers with the ERBB2 inhibitor herceptin and the proteasome inhibitor bortezomib, shows a synergistic growth inhibitory effect by preventing nuclear factor-kappaB (NFkappaB) activation and induction of nuclear accumulation of the cyclin-dependent kinase inhibitor p27(kip1). 33 An additional line of evidence suggests that bortezomib could increase the level of PTEN and inhibit the downstream pathway of ERBB2, interfering with phosphorylation of AKT, and enhance herceptin-induced growth inhibition in herceptin-resistant cells. 34 Bortezomib has an excellent therapeutic potential in organotypic culture and in vivo models of ESCC 29,36--39 and ESCC patients who failed to respond to the standard chemoradiotherapy approach targeting mitochondrial apoptotic pathways. 29, 30 In ESCC, bortezomib robustly induces p53-independent apoptosis associated with caspase cleavage and G2-M-phase cell cycle arrest via altering MAPKactivity. 35 Notably, suppression of 20S proteolytic core activity by bortezomib affects the degradation rates of many regulatory short-lived proteins, which expression levels and/or activity depend upon polyubiqutination and deubiqutination rates. Recent studies on proteasome-dependent proteolysis of ubiquitinated eIF4E revealed that while ubiquitinated eIF4E retains its cap binding ability, eIF4E phosphorylation and eIF4G binding are reduced. 32 It was also shown the eIF4G is cleaved by the 20S proteasome. 33 Suppression of 20S proteasomal activity with UPSspecific inhibitor decreased amount of cap-bound eIF4G thereby suppressing cap-dependent translation. 34 Thus, presumably, targeting UPS in ERBB2-positive cancers with aberrantly activated eIF4F might be a novel and more efficient therapeutic strategy compared to a standard chemoradiotherapy that predominantly targets the mitochondrial apoptotic pathway.
A corollary of our concept is that disruption of aberrantly activated eIF4F function downstream of amplified ERBB2 will be an effective anti-cancer strategy; and that targeting the UPS could increase the efficacy of therapeutics targeting cap-dependent translation. Thus, the goal of this investigation was to determine whether ERBB2-positive EACs harbor a constitutively activated cap-dependent translation that contributes to the malignant phenotype; and if so, then determine whether inhibition of the UPS with bortezomib would show synergistic growth-inhibitory effect with genetic/pharmacological targeting of the eIF4F. Our studies show that aberrantly activated eIF4F and the deregulated proteasome system collaborate as part of the molecular strategy adopted by esophageal cancer cells to maintain neoplastic growth; and identify interruption of this pro-oncogenic cooperation as a novel therapeutic approach.
MATERIAL AND METHODS

Tissue samples, cell lines and constructs
The study complied with the Declaration of Helsinki. Normal and malignant (adenocarcinoma) esophageal tissue samples (n ¼ 12) were obtained from the Cooperative Human Tissue Network and from the clinical esophageal cancer practice at the University of Minnesota using Institutional Review Board approved protocols. All patients gave written informed consent before surgery. Mucosal samples were dissected from underlying tissue then flash frozen in liquid nitrogen prior to storage at À80 1C. Authenticated EAC cell lines (OE19, OE33) were purchased from the European Collection of Cell Cultures (ECACC) and maintained in RPMI-1640 growth medium (Mediatech, Inc.) supplemented with 10% fetal calf serum (FCS, Sigma) and antibiotic/antimycotic (GIBCO).
To introduce the phosphorylation site double mutant of 4E-BP1 (4E-BP1 A37/A46 ) we used the retroviral expression vector MSCV-M1GR1 (Clontech), which encodes GFP to identify successfully transduced cells and a 3HA-tagged 4E-BP1 gene (MSCV-M1GR1-GFP/HA-4E-BP1
A37/A46
). 12, 35 MSCV-M1GR1-GFP was used as a vector control. Retroviral transfection was performed as described previously. 12 Cells with high, medium, and low levels of GFP-expression were then subject to western assay to assess expression of exogenous 4E-BP1 (HA-4E-BP1
). Cells with a medium level of GFP were used in all experiments.
Analysis of cell growth
Cell growth was analyzed by cell counting: 1.5 Â 10 4 cells/well were plated in 6 well clusters. Next day number of attached cells was calculated (accepted as '0 day' point). Attached cells were then grown in the presence or absence of 50 nM rapamycin for 6 days and counted.
Western assay and antibodies
For rapamycin-treatment experiments, 10 5 cells were plated in 6-well clusters in complete media. 24 h later, cells were serum deprived for 48 h and then incubated in complete media with or without 50 nM rapamycin (Sigma) for 6 h. After treatment, cells lysates were subject to Western assay as described.
12 eIF4E antibody was from BD Transduction Laboratories, HA and actin antibody were from Sigma, and 4E-BP1 from Abcam. eIF4G1 antibody was obtained from N. Sonenberg. Antibodies against MAPK, Akt, p70S6 K and their phosphorylated forms were from Cell Signaling. Phospho-p70 S6 K antibody was from Upstate. Samples from two independent experiments were analyzed with each primary antibody.
In vitro cap-affinity assay ( m7 GTP Pull-down)
Cap-binding assay ( m7 GTP-sepharose micro scale affinity chromatography) was performed as described. 12, 35 Supernatants from two independent experiments were subject to Western assay.
Quantification of global cap-dependent translation
To quantify the global level of cap-dependent translation, we utilized a bicistronic reporter system (pcDNA-rLuc-polIRES-fLuc) as described previously. 35 To assess the effect of rapamycin on translation of the luciferase reporter, 48 h after transfection with the bi-cistronic plasmid, cells were incubated in media with or without 50uM rapamycin for 24 h.
Anchorage-dependent colony formation 10 3 cells were seeded into 6-well clusters. Cultures were continued for 10 days in the presence or absence of 25 nM or 50 nM rapamycin or 25 nM bortezomib (PS341), fixed with 4% formaldehyde, and stained with Coomassie Blue. 
RESULTS
Esophageal adenocarcinomas with amplified ERBB2 harbor a hyperactivated eIF4F complex Our previous studies have revealed that up to 40% of EAC display amplification of the ErbB2 gene.
1,2 Two examples are OE19 (100-fold ErbB2 gene amplification) and OE33 (14-fold ErbB2 amplification) EAC cell lines. Both show dramatic increases in ERBB2 protein levels compared to an immortalized esophageal epithelial cell line, HET-1A ( Figure 1a ). Here we explored whether inhibition of ERBB2 with herceptin (Trastuzumab), an FDA approved therapeutic monoclonal antibody for ERBB2 protein overexpressing metastatic breast cancer, alters ERBB2-positive EAC cell growth and the expression of two major mTOR targets regulating mRNA translation: p70S6K and 4E-BP1 (Figures 1b-d) .
In both cell lines herceptin impeded clonogenic expansion ( Figure 1b) . We did not observe any changes in total MAPK or p-MAPK expression upon herceptin treatment (data not shown). Both, p-P70S6K and 4E-BP1 levels, two major downstream targets for mTOR-kinase were decreased following treatment with 50 or 100 mg/ml of Herceptin ( Figure 1c ). In line with published studies in breast cancer, 40 treatment of OE19 esophageal cancer cells with 10 mg/ml of herceptin decreased the levels of phosphorylated AKT. The effect of a PI3K inhibitor, LY294002, on p-AKT expression was more pronounced. The combination of herceptin and LY294002 was synergistic and resulted in complete abrogation of p-AKT expression. These molecular changes were associated with alleviated cell growth upon treatment with herceptin ( Figure 1d ).
We next explored whether direct genetic targeting of ERBB2 with anti-ERBB2 siRNA in the OE19 cell line would produce results similar to herceptin treatment. 72 h post-siRNA treatment, proliferation rate of OE19 cells was reduced by 50% ( Figure 1e ). This was associated with the significant decrease in 4E-BP1 phosphorylation ( Figure 1f , top panel). p70S6K phosphorylation was greater than after herceptin treatment. We also sought to determine whether expression of specific oncogenic proteins regulated by ERBB2 signaling at the level of mRNA translation, i.e. 'ERBB2-specific targets', would be altered upon ErbB2 knockdown with siRNA. The expression of p16, Src and Cyclin D1 was down regulated in response to ErbB2-siRNA ( Figure 1f , bottom panel), similar to osteopontin (not shown). Real-time PCR analysis confirmed that for osteopontin, cyclin D1 and p16, this effect was mediated by altered translation rather than changes in mRNA abundance (not shown). Thus, our experimental results suggest that translational control has a role in ERBB2 signaling.
We further explored whether targeting ERBB2 with herceptin leads to altered cap-dependent mRNA translation. We assessed the integrity of the eIF4F complex in EAC cells. This assay quantifies the relative binding of eIF4G1 (translationally active complex) versus 4E-BP1 (translationally inert complex) to total cellular eIF4E. 9, 13, 35, 41 Cellular eIF4E was purified using m 7 -GTP sepharose (cap-analogue), and the presence of 4E-BP1 and eIF4G1 was assessed by western blot (Figure 1g ). In both cell lines, independent of the steady state levels of eIF4E, eIF4G1 and 4E-BP1; there was an increase in the relative amount of 4E-BP1 bound to cap-captured eIF4E compared to eIF4G after treatment with herceptin. This indicates that targeting ERBB2 negatively regulates translation in EAC cell lines.
Activation of eIF4F in esophageal cancer Pathologic redirection of translational control by constitutive activation of eukaryotic translation initiation factor 4E (eIF4E) is one of the well documented obligatory steps in oncogenesis where sustained activation of eIF4F also has a causal role in malignant transformation. 10--14 Recent clinical studies on the analysis of tissue samples obtained from 99 patients with esophageal cancer showed that levels of both eIF4E and 4E-BP1 are elevated in tumors compared to noncancerous esophageal tissues. 24 Because increased levels of eIF4E and 4E-BP1 might indicate constitutive activation of the cap-dependent translation and considered as potential predictive biomarkers for neoplastic growth and eIF4F-targeted therapy, 13, 42 we first sought to determine the integrity and functional activity of the translation complex eIF4F in human esophageal tumor tissue. We conducted a cap-binding assay in lysates of tumor tissue specimens and adjacent normal esophageal mucosa derived from the same patient (Figure 2a) . We found elevated levels of cap-bound eIF4G1 in 80% of tumors compared to normal tissue (Figure 2b ). There was an average 10-fold increase in cap-captured eIF4G1 compared to normal tissue (Pp0.05). This dramatic increase in eIF4G1 bound to eIF4E in tumor tissue indicates that EAC is in a translationally active state.
Furthermore, we compared the abundance of eIF4F components on 7m GTP cap in immortalized HET-1A cell line bearing a single copy of ERBB2 and 2 EAC cell lines with different level of ERBB2: OE19 and OE33 (Figure 2c ). Levels of eIF4G1 were increased in both tested ErbB2-amplified EAC cell lines compared to HET-1A cells with single copy of ErbB2 gene. Thus, our results are in a good agreement with the previously published works establishing the presence and abundance of eIF4G1 on 7m GTP cap as a marker of the translationally active eIF4F complex. 21, 25, 41, 43 Importantly, level of cap-bound eIF4G1 was dependent on extracellular growth signaling in OE33 cells (Figure 2d ). Whereas in OE19 cells with over a hundred-fold amplified ErbB2, level of cap-bound eIF4G1 remained the same with no regard of the presence or absence of growth serum. This result suggests uncoupling of growth--factor signaling and regulation of capdependent translation in cells with high level of ErbB2 amplification. Altogether, our results strongly support the hypothesis on constitutive hyper-activation of translational machinery in both, EAC tumor specimens and EAC cell lines compared to normal samples; and the status of the translational apparatus dependent on the level of ErbB2-amplification.
Based on these findings, we proposed that the suppression of hyper-activated translational apparatus might serve as a useful strategy in treatment of EAC cancers in general and those overexpressing ERBB2 in particular. Therefore, we next explored the possibility to suppress cap-dependent translation in EAC cell lines by using pharmacological and direct genetic targeting approaches.
Targeting mRNA translation One of the major properties of the mTOR-kinase inhibitor, rapamycin, is its ability to suppress 4E-BP1 phosphorylation and thus to negatively regulate cap-dependent translation initiation via increasing 4E-BP1 level bound to cap. 18,43--45 In order to determine whether suppression of cap-dependent translation would inhibit ERBB2-EAC cell growth, we evaluated the effect of rapamycin on cap-dependent translation and cell number. Rapamycin significantly suppressed cell growth (Pp0.05) (Figure 3a ) and anchorage-dependent colony formation in both cell lines (Figure 3b) . In OE33 cells, rapamycin had the most pronounced effect and suppressed both, colony number and size, whereas in OE19 cells the predominant effect was only on colony size. We further explored whether growth-inhibitory properties of rapamycin are associated with altered cap-dependent mRNA translation in EAC cell lines. Accordingly, we quantified the impact of rapamycin on the translation in OE19 and OE33 cells transiently transfected with the generic bicistronic translation reporter vector (Figure 3c ). Bicistronic vectors, in which the renilla luciferase gene is encoded in the first cistron and the firefly luciferase gene is encoded in the second cistron, with IRES separating the two cistrons, are routinely used for translational studies. At doses effective in suppression of cell growth, rapamycin suppressed capdependent translation (renilla luciferase) in OE33 cells (Pp0.05) but not in OE19 cells. In OE33 cells, the greater suppression of cap dependent translation by rapamycin (Figure 3c , 60% of DMSO control) was associated with higher suppression of cell growth (Figure 3a , 70% by day six). In contrast, growth inhibitory effect of rapamycin in OE19 cell line (Figure 3a , 60% of DMSO control) was not associated with the suppression of translation (Figure 3c) suggesting that the inhibitory effect of rapamycin might be due to targets other than 4E-BP1. To explore this possibility, we performed western blot analysis of serum-deprived cells stimulated by the addition of 10% serum and treated with rapamycin for 6 h ( Figure 3d ). As expected, serum withdrawal led to de-phosphorylation of 4E-BP1 (data not shown), and addition of 10% serum promoted rapid hyperphosphorylation of 4E-BP1 (g isoform, Figure 3d , top gel, top band). Rapamycin prevented serum-induced hyperphosphorylation of 4E-BP1 in both cell lines tested with a greater effect in the OE33 cell line. Surprisingly, serum deprivation did not cause de-phosphorylation of another m-TOR kinase target, p70S6 kinase, on its serum and rapamycin-sensitive phosphorylation site (Thr389) in both cell lines (not shown). Consistently, because p70S6K phosphorylation in these cell lines did not (or only partially) depend on mTOR-mediated growth factor signaling, we were not able to detect changes in phosphorylation of p70S6K in rapamycin-treated OE33 cells (Figure 3d ) as previously described for other cancer cell lines of different origin. 45, 46 In OE19 cell line, rapamycin effectively inhibited p70S6K phosphorylation. Furthermore, in accordance with published evidence on feedback activation of AKT by rapamycin in different cancer cell lines, 47, 48 we observed slight activation of AKT in OE19 cells as measured by its phosphorylation at Ser473. Moreover, western blot analysis revealed activation of MAPK in OE19 cells as reflected by its phosphorylation on Thr202/Tyr 204 sites. In OE19 cells, rapamycin effectively inhibited MAPK phosphorylation on these sites. It should be noted that activated MAPK is responsible for Mnk-1-mediated phosphorylation of eIF4E, an event that increases binding of eIF4E to the mRNA cap with resultant activation of cap-dependent translation initiation. 49 Altogether, these results suggest that OE19 cells harbor growth-factor independent activation of AKT/mTOR and MAPK-signaling, and possibly other pathways, uncoupling effect of rapamycin on cell growth and cap-dependent translation.
Previous reports on breast cancers show that overexpression of ErbB2 as a result of gene amplification leads to aberrant signaling downstream of major RAS/MAPK and PI3K/AKT/mTOR oncogenic signaling pathways, 40 presumably modulating the level of mRNA translation. Therefore, we proposed that highly amplified ErbB2 in OE19 cells might be responsible for the differential effect of rapamycin on translation and the level of ErbB2 in OE19 cells dramatically exceeding one in OE33 cells might represent one of the valid mechanisms explaining the molecular basis for uncoupled cell growth and cap-dependent translation in a highly ErbB2-amplified OE19 cell line.
To assess whether direct targeting of the translation complex eIF4F would be more efficient strategy compared to rapamycin treatment in EAC with different level of ErbB2 amplification, we next applied 'gain-of function' approach by overexpressing 4E-BP1 in EAC cell lines. To directly target eIF4F integrity, we used a vector encoding a double phosphorylation site mutant form of 4E-BP1 gene (4E-BP1 A36/A47 , designated 'TTAA') that resists inactivation by hyperphosphorylation through the PI3K/Akt/mTOR cascade and compared its effect to a vector encoding wild type 4E-BP1 (WT) and an empty vector control. To identify cells expressing the construct, all vectors also encoded GFP. HA-tagged TTAA, HA-WT and empty vector cells were first sorted by GFP intensity and cells with a medium level of GFP (mean ± 1 s.d.) were selected for use. The expression levels of exogenous BP1 in both OE19 and OE33 cell lines were comparable as determined by western blot with anti-HA-tag and anti-4E-BP1 (Figure 4a) . We verified the ability of exogenous TTAA to participate in the assembly of eIF4F initiation complex by cap-analogue capture of eIF4E and its binding partners, 4E-BP1 and eIF4G1, in TTAA and empty vector lysates followed by western blot analysis (Figure 4b ). Both cell lines expressed equal levels of exogenous TTAA (Figure 4a ) which was also able to bind to eIF4E (Figure 4b ). We further accessed the capacity of exogenous BP1 proteins to form functionally active eIF4F complex based on its ability to release eIF4G1 from the cap in response to nutrient deprivation. Wild-type 4E-BP1 (WT) or TTAA cells were grown in the presence or absence of serum and lysates were subjected to western blot analysis to assess the expression and the ability of exogenous WT and TTAA BP1 to bind to eIF4E (Figure 4c ). Because we found that expression levels of exogenous WT were low, and expression of the protein of interest was dependent on the presence of serum, we used TTAAtransgenic cell lines for future studies. In these cells, introduction of TTAA decreased the level of cap-bound eIF4G1, indicating that TTAA forms functional eI4F and cap-dependent translation is suppressed in response to serum withdraw. We confirmed these findings by measuring the translation of the luciferase reporter (Figure 4d ). Decrease in translation of renilla luciferase in both, TTAA-OE33 and TTAA-OE19 cells, compared to vector control also indicated TTAA 4E-BP1 was an effective translational repressor. Altogether, these results show that direct genetic targeting of eIF4F is a valuable strategy to overcome the aberrant ErbB2-signaling in EAC and direct targeting of translation initiation complex eIF4F is a more effective approach than treatment with rapamycin.
Disruption of eIF4F integrity inhibits clonogenic growth, proliferation and apoptosis Previously published observations using different models have shown that genetic targeting of eIF4F by ectopic expression of tumor suppressor 4E-BP1 reverts the malignant phenotype in cells transformed by eIF4E, Src, or Ras; 50,51 promotes apoptosis; and diminishes tumorigenicity of Ras-transformed cells. 50 Moreover, mutant forms of 4E-BP1, including TTAA, which cannot be inactivated by hyperphosphorylation, stimulate apoptosis and inhibit tumorigenicity when expressed in human breast carcinoma cells. 12 To determine whether suppression of cap-dependent translation by 4E-BP1 negatively regulates the malignant phenotype of ERBB2-positive EAC cell lines, we examined focus formation and cell cycle dynamics in TTAA and vector control OE19 and OE33 cells. TTAA significantly suppressed anchoragedependent clonogenicity (Figure 5a ) and cell growth (Figure 5b genotype (Pp0.0001) and the interaction of both factors (Pp0.02) as assessed by two-factor ANOVA. To determine the cellular mechanisms by which TTAA affects growth and clonogenicity, we performed FACS analysis of propidium iodide stained cells. TTAA impeded G1/S checkpoint progression in both cell lines (Pp0.05) and, induced apoptosis (sub-G1) in OE33 cells (Figures 5c and d) . Thus, over-expression of a constitutively active form of 4E-BP1 was sufficient to decrease the level of cap-dependent translation in both cell lines tested, including OE19 with highly-amplified ErbB2. This effect was accompanied by suppression of anchoragedependent clonogenicity. Moreover, over expression of 4E-BP1 inhibited cell growth by 2 different mechanisms: blocking G1/S progression or simultaneous blocking G1/S progression and induction of apoptosis.
Synergistic effect of cap-dependent translation and the ubiquitinproteasome system targeting Although the molecular mechanisms underlying coordinated regulation of protein synthesis and degradation is not yet fully understood, published evidence suggest that the expression and functional activity of eIF4E and eIF4G1, are regulated in part via ubiquitin-proteasome-mediated mechanisms. 32--34 Accordingly, inhibition of the 20S proteasome core activity with UPS specific inhibitors prevents cleavage and stabilizes eIF4E and eIF4G1, decreases amount of cap-bound eIF4G1 32, 34 and as a result differentially affects translation of different mRNAs. 33 Bortezomib, UPS inhibitor, also produces a dramatic (20-to 40-fold) sequential increase in polyubiquitinated ERBB2. 32 To determine if pharmacological targeting of cap-dependent translation might sensitize EAC cells to bortezomib, OE33 cells were mock-treated or treated with suboptimal doses of bortezomib (6 nM), rapamycin (25 nM) or a combination of bortezomib and rapamycin (6 and 25 nm, respectively). The combination treatment was highly synergetic with a combination indices (CI) of only 0.197 and resulted in a 28% reduction in cell proliferation compared to treatment with single agents alone (Figure 6a ).
Because we established that direct targeting of eIF4F has certain advantage in ERBB2-positive EAC as compared to treatment with rapamycin, we next sought to address whether targeting UPS with bortezomib could increase the efficacy of potential therapeutics directly targeting eIF4F, and thus would be a novel therapeutic strategy in EAC treatment. Accordingly, we measured cell viability/growth in OE33 cells harboring TTAA or vector treated with or without bortezomib (Figure 6b ). After treatment with bortezomib, growth of TTAA was inhibited more than 50% compared to vector control. The IC 50 for vector cells was more than 20-fold higher than for TTAA (149.5 nM for vector versus 5.8 nM for TTAA; Pp0.001). Examination of clonogenic growth revealed that inhibition of cap-dependent translation via both, genetic (TTAA) or pharmacological (rapamycin) targeting, and inhibition of the UPS (bortezomib) results in suppression of anchorage-dependent colony formation. While the combination of rapamycin and bortezomib showed some synergy in suppressing colony formation, direct targeting of cap-dependent translation (TTAA) together with bortezomib nearly ablated all colony formation (Figure 6c) . Thus, targeting cap-dependent translation by both, direct and indirect approaches profoundly sensitizes esophageal cancer cells to the inhibition of UPS functions with bortezomib and therefore, the combination of bortezomib and novel eIF4F inhibitors or upstream mTORC1 inhibitors might be a novel therapeutic strategy for EAC patients.
DISCUSSION
Among the functions of the several hundred known cancer genes, is the usurping of the cellular machinery governing posttranscriptional control. Translation and protein degradation are the two fundamental cellular processes determining proteome structure at the post-transcriptional level; and are tightly regulated by the extracellular and metabolic signals. 50 Here we show that co-targeting 2 crucial steps of the post-transcriptional control, the cap-dependent translation initiation complex (eIF4F) and the ubiquitin-proteasome system (UPS) synergistically attenuates the esophageal adenocarcinoma (EAC) phenotype.
Our results demonstrate that cap-dependent mRNA translation, a step near the apex of the post-transcriptional control, is activated in most tested EAC cell lines and tumors (Figures 1  and 2) , and that targeted disruption of eIF4F abrogates the malignant phenotype (Figures 3--5 ). These findings are in accord with the published data obtained in different cancer models. 10--14 In principle, normalizing deregulated eIF4F-mediated translation can be accomplished indirectly by interrupting upstream signaling leading to eIF4F activation or by direct targeting of the eIF4F complex. There is ample evidence supporting the role of eIF4F activator mTOR in a variety of cancers and in cancer therapy. 52, 53 Although the mTOR attracts attention as a valuable target, acquired resistance to anti-mTOR therapeutics is a major problem for their clinical applications. The very recent evidence suggests that the activity of the translation apparatus predicts sensitivity to mTOR inhibition. 54 Specifically, it is shown that eIF4E activity is a significant predictor of rapamycin sensitivity in cell lines and tumors of different origin, with higher eIF4E activities indicative of enhanced sensitivity; however, eIF4E is further deregulated in tumors in response to mTOR inhibition. This suggests that direct attacking eIF4F can be the most favorable strategy for targeting aberrant cap-dependent translation.
In this study, we compared efficiencies of indirect and direct approaches for targeting of eIF4F. As an indirect approach, we used the mTOR inhibitor rapamycin. Our approach for direct genetic targeting of eIF4F is based on antagonizing association of the cap-binding protein eIF4E with the scaffold protein eIF4G1 by introduction of the gene encoding the double phosphorylation site mutant form of 4E-BP1 (4E-BP1 A36/A47 , designated here as 'TTAA'). We show that expression of constitutively active mutant form of the translational repressor TTAA not only effectively reduces translation in rapamycin resistant cells, but also efficiently alleviates basic cancer-associated features, including cell growth, proliferation, colony formation, and in OE33 cells also resistance to apoptosis. Our data indicate that direct genetic targeting of eIF4F by constitutively active form of 4E-BP1 is more effective than pharmacological mTOR inhibition by rapamycin (Figures 3--5) . Additionally, another established reason for limited efficacy of mTOR inhibitors is a suppression of mTOR regulated negative feedback loops, which leads to pro-oncogenic activation of the upstream growth factor receptor signaling. 47, 48 Consistently, our data demonstrate that the effect of rapamycin on cancer-related capabilities of OE19 EAC cell line is attenuated by its pleiotropic effects resultant in interruption of the m-TOR negative feedback signaling and activation of the pro-oncogenic AKT pathway (Figure 3d) . Thus, despite suppressing 4E-BP1 phosphorylation, this desirable effect of rapamycin is offset by off-target effects and unintended activation of feed-forward loops. Taken together, this finding clearly show advantages of direct targeting eIF4F as an approach for normalizing cap-dependent translation in cancer cells and support current discoveries of drugs that target eIF4F by disrupting the integrity of eIF4F or antagonizing the eIF4E-mRNA cap interaction. 50 Based on these results, we next examined whether targeting the post-transcriptional pathway further downstream---at the UPS---would augment the effect of targeting eIF4F. Our data indicate that targeting cap-dependent translation by both, direct and indirect approaches profoundly sensitized esophageal cancer cells to the inhibition of UPS functions with bortezomib ( Figures  6a and b) . Of note, we also found that while rapamycin and bortezomib synergize in suppression of clonogenicity, direct genetic targeting of cap-dependent translation combined with treatment with bortezomib has a greater synergistic effect and completely abrogates clonogenicity (Figure 6c ). While we were preparing this manuscript for publication, others have documented synergism between mTOR and the UPS inhibitors in other cancer models, including multiple myeloma, 55 leukemia 56 and glioma. 57 After this current manuscript was accepted for publication, our collaborators have brilliantly established the mechanistic basis underlying the putative potency of combinatory treatment with bortezomib and antisense eIF4E as anti-cancer regimen. 58 Available evidence now indicates that in order to commandeer post-transcriptional control, many cancers usurp the cap-dependent translation machinery and the UPS. Accordingly, our findings indicate that neoplastic growth is critically dependent on mRNA translation rates and ubiquitin-proteasome activity and that cooperation between these two systems is necessary for cancer susceptibility. These data support our hypothesis that a well-tuned interrelationship between up-regulated cap-dependent mRNA translation and UPS activity is an essential component of metabolic homeostasis required for maintenance of the malignant phenotype. Based on our findings, we propose the translation complex eIF4F and UPS as novel targets for combinational therapy of esophageal cancers.
There has been substantial interest in improving anti-UPS therapy in other types of cancers with particular attention to cotargeting UPS and the receptor signaling pathways. To date, this strategy has not been completely validated mainly due to the ability of cancer cells to rapidly adapt to inhibition of signal suppression (inactivation of a particular pathway frequently leads to activation of pro-oncogenic collateral signaling circuits). Our findings indicate that esophageal carcinoma cells require both, upregulated eIF4F-mediated translation and the active function of the ubiquitin-proteasome machinery, for their viability and proliferation, and that cooperation between these two systems is necessary for the cancer progression. Thus, the results of the present study provide a rationale for a novel one-hit approach for the cardinal improvement of anti-UPS therapy, which targets several key oncogenic pathways including the ERBB2/PI3K/AKT, RAS/MAPK and mTOR signaling cascades by attacking their downstream convergence point---eIF4F. Of note, our results provide the rationale for clinical trials evaluating the combination of FDA-approved inhibitors rapamycin and bortezomib (PS341) as a novel combination for the EAC treatment.
